Skip to main content

Position for Biotech Rebound With Quality Names

Broadly speaking, 2021 hasn’t been kind to biotechnology stocks and exchange traded funds, but some market participants remain optimistic regarding a rebound for these previously beloved assets. One way investors can position for such an event is to lean toward higher quality, less...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.